Comparative Efficacy of Amoxicillin vs. Azithromycin in the Treatment of Community-Acquired Pneumonia
Keywords:
Amoxicillin, azithromycin, Pediatric Pneumonia, Community-acquired pneumoniaAbstract
Background: Globally, community-acquired pneumonia (CAP) ranks high among the leading causes of death and disability. Antibiotics should be started as soon as possible. Although there is a growing availability of different pharmacological alternatives for CAP, there is sometimes insufficient information to directly compare the effectiveness of these treatments.
Objective: The primary goal of this research is to compare the effectiveness of azithromycin and amoxicillin in treating pneumonia in children.
Materials and Methods: In all, 152 individuals were found to be suffering from pneumonia. The patients were split into two categories. Six days of amoxicillin at 50 mg/kg/day, split into three doses, is administered to patients in group I. The dosage of azithromycin for patients in group II is 10 mg/kg on day one, followed by 5 mg/kg daily for four days. On days 2, 4, and 6, we looked for signs of improvement in overall health, such as a drop in temperature, less respiratory symptoms, and no longer feeling sick.
Results: There were majority males in both groups. Mean age of the cases in group I was 5.13±4.19 years and in group II mean age was 6.9±4.12 years.In terms of clinical improvement rates by Day 6, 92.1% for amoxicillin and 85.5% for azithromycin (p = 0.51) and radiographic recovery rates by Day 6, 68 (89.5%) for amoxicillin and 64 (84.1%) for azithromycin (p = 0.40), no statistically significant differences were found.
Conclusion: We found no statistically significant differences between amoxicillin and azithromycin in terms of clinical outcomes, microbiological eradication, or side effects; therefore, both antibiotics are safe and effective in treating pediatric community-acquired pneumonia
Downloads
Metrics
References
Ferreira-Coimbra J, Sarda C, andRello J. Burden of community-acquired pneumonia and unmet clinical needs. AdvTher 2020; 37: 1302–1318. Available from: /pmc/articles/PMC7140754/
Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 2017; 65: 1806–1812.
ABCs 2018 Strep pneumoniae report | CDC [Internet]. [cited 2021 Apr 25]. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.html
Ynthia W, Hitney CG, Onica F, Arley MM, Ames Adler JH, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. Vol. 343. 1917.
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J RespirCrit Care Med 2019; 200: E45–E67.
Vardakas KZ, Trigkidis KK, andFalagas ME. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. ClinMicrobiol Infect 2017; 23: 234–241.
Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36: 612–620.
Karhu J, Ala-Kokko TI, Ohtonen P, et al. Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination. ActaAnaesthesiolScand 2013; 57: 587–593.
Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies. Respiration. 2017;94(3):299–311
Muthumbi E, Lowe BS, Muyodi C, Getambu E, Gleeson F, Scott JAG. Risk factors for community-acquired pneumonia among adults in Kenya: a case-control study. Pneumonia (Nathan) [Internet]. 2017 Dec [cited 2022 Dec 17];9(1).
Eshwara V, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. Indian Journal of Medi-cal Research. 2020;151(4):287.
Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, et al. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European Journal of Clinical Microbiology & Infectious Diseases. 2020 Aug 3;39(8):1513–25.
Nambafu J, Achakolong M, Mwendwa F, Bwika J, Riunga F, Gitau S, et al. A prospective observational study of community acquired pneumonia in Kenya: the role of viral pathogens. BMC Infect Dis. 2021 Dec 23;21(1):70
Jain V, Vashisht R, Yilmaz G, Bhardwaj A. Pneumonia Pathology. StatPearls [Internet]. 2022 Aug 1 [cited 2022 Dec 18]; Availa-ble from: https://www.ncbi.nlm.nih.gov/books/NBK526116/
Melese, M., Alemayehu, W., Lakew, T., Yi, E., House, J., Chidambaram, J. D., ... &Lietman, T. M. (2008). Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma.Jama,299(7), 778-784.
Melo, J. S., Aragie, S., Chernet, A., Tadesse, Z., Dagnew, A., Hailu, D., ... & Keenan, J. D. (2021). Targeted antibiotics for trachoma: a cluster-randomized trial.Clinical Infectious Diseases,73(6), 979-986.
Dresser LD, Niederman MS, andPaladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2019; 119: 1439–1448.
Torres A, Muir J, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. EurRespir J 2018; 21: 135–143.
Lodise TP, Kwa A, Cosier L, et al. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2019; 51: 3977–3982.
Dudas V, Hopefl A, Jacobs R, et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2018; 34: 446–452.
Hamao N, Ito I, Konishi S, et al. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial. BMC Pulm Med 2020; 20: 160.
Muthumbi, E., Lowe, B. S., Muyodi, C., Getambu, E., Gleeson, F., & Scott, J. A. G. (2017). Risk factors for community-acquired pneumonia among adults in Kenya: a case-control study. Pneumonia (Nathan Qld.), 9(1). H
Lee, M. S., Oh, J. Y., Kang, C. I., Kim, E. S., Park, S., Rhee, C. K., Jung, J. Y., Jo, K. W., Heo, E. Y., Park, D. A., Suh, G. Y., &Kiem, S. (2018). Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia. Infection & Chemotherapy, 50(2), 160.
Behnamfar, Z., Shahkarami, V., Sohrabi, S., Aghdam, A. S., &Afzali, H. (2019). Cost and effectiveness analysis of the diagnostic and therapeutic approaches of group A Streptococcus pharyngitis management in Iran.Journal of Family Medicine and Primary Care,8(9), 2942-2949.
Van Hecke, O., Wang, K., Lee, J. J., Roberts, N. W., & Butler, C. C. (2017). Implications of antibiotic resistance for patients’ recovery from common infections in the community: a systematic review and meta-analysis.Clinical Infectious Diseases,65(3), 371-382.
Kalos, A. P. (2015).The effect of azithromycin on the non-surgical treatment of peri-implantitis. A prospective double blind placebo controlled randomised clinical trial. A pilot study(Doctoral dissertation).
Mills G.D.OehleyM.R.Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.BMJ. 2005; 330: 456
Xiong, T., Yue, Y., Li, W. X., Choonara, I., Qazi, S., Chen, H. J., ...& Mu, D. Z. (2021). Effectiveness of azithromycin mass drug administration on trachoma: a systematic review.Chinese medical journal,134(24), 2944-2953.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
